 |
|
Searching for a Biomarker for Ovarian Cancer
James Allen Roberts, MD, MS
JAMA. 1998;280:739.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
This year 25400 women will be told that they have ovarian cancer. Over the next 3 to 5 years 14500 of them will die from their disease.1 Although these statistics are disturbing, they do not provide a complete image of what this truly means in terms of human suffering. Most of these women will undergo several major surgeries, multiple courses of chemotherapy treatment with their associated toxic effects, and several bouts of bowel dysfunction. They also will endure the psychological trauma of battling cancer before they die of their disease. In nearly every case, this morbidity and mortality are the result of a late diagnosis, with more than 50% of these women already having advanced to stage III or IV at the first physical signs of disease. An estimated 90% of these women (at least 13100) might be spared all of this, with no change . . . [Full Text of this Article]
From the Department of Gynecology and Obstetrics, Stanford University School of Medicine, Stanford, Calif.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers
Yan Xu, Zhongzhou Shen, Donald W. Wiper, Minzhi Wu, Richard E. Morton, Paul Elson, Alexander W. Kennedy, Jerome Belinson, Maurie Markman, and Graham Casey
JAMA. 1998;280(8):719-723.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Potential New Marker for Ovarian Cancer
JWatch General 1998;1998:2-2.
FULL TEXT
|
